{"protocolSection":{"identificationModule":{"nctId":"NCT01680900","orgStudyIdInfo":{"id":"816164"},"organization":{"fullName":"University of Pennsylvania","class":"OTHER"},"briefTitle":"Vilazodone for Menopausal Hot Flashes","officialTitle":"Vilazodone for Menopausal Hot Flashes: A Proof in Principle Study"},"statusModule":{"statusVerifiedDate":"2014-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-11"},"primaryCompletionDateStruct":{"date":"2013-08","type":"ACTUAL"},"completionDateStruct":{"date":"2013-08","type":"ACTUAL"},"studyFirstSubmitDate":"2012-08-28","studyFirstSubmitQcDate":"2012-09-06","studyFirstPostDateStruct":{"date":"2012-09-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-12-04","resultsFirstSubmitQcDate":"2015-01-13","resultsFirstPostDateStruct":{"date":"2015-01-14","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-01-13","lastUpdatePostDateStruct":{"date":"2015-01-14","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ellen Freeman","investigatorTitle":"Research Profesor","investigatorAffiliation":"University of Pennsylvania"},"leadSponsor":{"name":"University of Pennsylvania","class":"OTHER"},"collaborators":[{"name":"Forest Laboratories","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is a pilot study to determine proof in principle that vilazodone, a selective serotonin reuptake inhibitor and 5HT1a agonist, reduces the frequency and severity of menopausal hot flashes relative to placebo. A secondary aim is to evaluate improvement in menopause-related quality of life.","detailedDescription":"This is a proposal to conduct a small clinical trial for proof in principle that vilazodone reduces the frequency and severity of menopausal hot flashes. An additional exploratory aim is to identify improvement in menopause-related quality of life. Healthy, perimenopausal women ages 45-60 with an average of 4 or more moderate or severe hot flashes/night sweats per day for 3 screening weeks will be randomized to 8 weeks of treatment in a 2:1 ratio of vilazodone or matching placebo pills. Flexible dosing of vilazodone will start at 10 mg once/day for 7 days, increase to 20 mg/day for 1 more week and increase to 40 mg once/day at week 3 if unimproved. The primary outcome assessments are the frequency and severity of hot flashes at week 4 and week 8 as assessed by prospective daily diaries (using 7-day mean scores from the daily diaries). The secondary outcome is clinical improvement, defined as hot flash frequency \\>=50% decrease from baseline. Treatment-emergent adverse events will be monitored and patient ratings of tolerability will be obtained."},"conditionsModule":{"conditions":["Hot Flushes"],"keywords":["menopause","hot flashes","vilazodone"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":36,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"experimental 1","type":"EXPERIMENTAL","description":"vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks","interventionNames":["Drug: vilazodone"]},{"label":"placebo capsules (sugar pill)","type":"PLACEBO_COMPARATOR","description":"Placebo capsules matched to the drug dose for 8 weeks","interventionNames":["Drug: placebo capsules"]}],"interventions":[{"type":"DRUG","name":"vilazodone","description":"capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.","armGroupLabels":["experimental 1"],"otherNames":["viibryd"]},{"type":"DRUG","name":"placebo capsules","description":"placebo capsules matched to drug capsules.","armGroupLabels":["placebo capsules (sugar pill)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Daily Diary Ratings of Frequency of Hot Flashes","description":"Hot flash frequency and severity will be recorded daily in the am and pm on a scale of 0 (none) to 3 (severe). The frequency of hot flashes was the number reported.","timeFrame":"Week 8."},{"measure":"Daily Diary Ratings of Severity of Hot Flashes","description":"Hot flash severity will be recorded daily in the am and pm on a scale of 0 (none) to 3 (severe). The frequency of hot flashes was the number reported. The severity of hot flashes was rated on a scale of 0 (none) to 3 (severe). 7-day averages were calculated for baseline, week 4 and week 8 and a mean daily score was obtained for analysis. Baseline values were the means of the first 2 screen weeks. Possible range of the severity scale for the daily mean was 0 (none) to 3 (severe).","timeFrame":"Week 8."}],"secondaryOutcomes":[{"measure":"Percent of Patients With >=50% Reduction in Moderate to Severe Hot Flashes","description":"Percent of patients with n \\>=50% reduction in frequency of moderate to severe hot flashes calculated from daily diaries","timeFrame":"Percent change from baseline at Week 8"},{"measure":"Menopause-related Quality of Life (MENQOL)","description":"The MENQOL is a validated measure to assess the presence and bother of menopausal symptoms. This will be exploratory. Each of 29 items is rated on a scale of 0 to 6 (extremely bothersome). The items are divided into 4 subscales. The item scores are summed in each subscale and means are computed for the 4 subscales. The total score is the sum of the mean subscale scores. Higher scores are more symptomatic.","timeFrame":"Week 8"}],"otherOutcomes":[{"measure":"Number of Participants With Adverse Events","description":"A 17 item checklist of general adverse and withdrawal symptoms. It will be used at baseline and Week 12. Adverse events will be obtained by subject report at Week 4 and Week 8.","timeFrame":"Baseline and Week 12"},{"measure":"Percentage of Participants That Were Satisfied or Very Satisfied","description":"Patient global rating of satisfaction with medication reported on a scale of 0 to 5 (very satisfied).","timeFrame":"Week 8"},{"measure":"Sheehan Global Ratings of Symptom (Hot Flash)Interference","description":"Global ratings on a 10-point scale of the degree that symptoms interfere overall, with work, social activities and family life.","timeFrame":"Change from Baseline at Week 8"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women ages 45-60 years\n* Amenorrhea for 60 days or more or postmenopausal or bi-lateral oophorectomy.\n* 4 or more moderate or severe hot flashes or night sweats per 24 hour period (28/week) as recorded on daily diaries in 3 screening weeks.\n* Hot flashes/night sweats rated as moderate to severe and/or bothersome (moderately to a lot) on 4 or more days/nights in each screen week.\n* In general good health.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Psychotropic medications currently or within the last 30 days.\n* Current use of hormonal medications such as hormone therapy or hormonal contraception or any treatment for hot flashes (Prescription, over-the-counter or herbal).\n* Drug or alcohol abuse in the past year.\n* Lifetime diagnosis of psychosis or bipolar disorder.\n* Suicide attempt in the past 3 years or any current suicidal ideation.\n* Current major depression.\n* Not using a medically approved, non-hormonal method of birth control if sexually active and not postmenopausal (12 or more months since last menstrual period or bi-lateral oophorectomy).\n* Pregnancy, intending pregnancy or breast feeding.\n* Any severe of unstable medical illness, e.g., breast or ovarian cancer, seizure disorders, etc.\n* Current participation in another intervention study.\n* Inability or unwillingness to complete study procedures.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"45 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Ellen W Freeman, PhD","affiliation":"University of Pennsylvania","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Dept OB/GYN, Mudd Professorship Suite","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Experimental 1","description":"vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks\n\nvilazodone: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved."},{"id":"FG001","title":"Placebo Capsules (Sugar Pill)","description":"Placebo capsules matched to the drug dose for 8 weeks\n\nplacebo capsules: placebo capsules matched to drug capsules."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Experimental 1","description":"vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks\n\nvilazodone: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved."},{"id":"BG001","title":"Placebo Capsules (Sugar Pill)","description":"Placebo capsules matched to the drug dose for 8 weeks\n\nplacebo capsules: placebo capsules matched to drug capsules."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"36"}]}],"measures":[{"title":"Age, Continuous","description":"self-reported age in years","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"51.5","spread":"3.7"},{"groupId":"BG001","value":"52.7","spread":"4.2"},{"groupId":"BG002","value":"51.9","spread":"3.9"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"36"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"36"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Daily Diary Ratings of Frequency of Hot Flashes","description":"Hot flash frequency and severity will be recorded daily in the am and pm on a scale of 0 (none) to 3 (severe). The frequency of hot flashes was the number reported.","populationDescription":"all participants randomized to treatment","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"number of hot flashes","timeFrame":"Week 8.","groups":[{"id":"OG000","title":"Experimental 1","description":"vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks\n\nvilazodone: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved."},{"id":"OG001","title":"Placebo Capsules (Sugar Pill)","description":"Placebo capsules matched to the drug dose for 8 weeks\n\nplacebo capsules: placebo capsules matched to drug capsules."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.65","lowerLimit":"2.57","upperLimit":"4.73"},{"groupId":"OG001","value":"4.71","lowerLimit":"3.61","upperLimit":"5.80"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.05","statisticalMethod":"Regression, Linear","paramType":"Mean Difference (Final Values)","paramValue":"-1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.60","ciUpperLimit":"-0.48"}]},{"type":"SECONDARY","title":"Percent of Patients With >=50% Reduction in Moderate to Severe Hot Flashes","description":"Percent of patients with n \\>=50% reduction in frequency of moderate to severe hot flashes calculated from daily diaries","populationDescription":"all participants with at least one treatment response","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Percent change from baseline at Week 8","groups":[{"id":"OG000","title":"Experimental 1","description":"vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks\n\nvilazodone: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved."},{"id":"OG001","title":"Placebo Capsules (Sugar Pill)","description":"Placebo capsules matched to the drug dose for 8 weeks\n\nplacebo capsules: placebo capsules matched to drug capsules."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"83"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.05","statisticalMethod":"Chi-squared","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Menopause-related Quality of Life (MENQOL)","description":"The MENQOL is a validated measure to assess the presence and bother of menopausal symptoms. This will be exploratory. Each of 29 items is rated on a scale of 0 to 6 (extremely bothersome). The items are divided into 4 subscales. The item scores are summed in each subscale and means are computed for the 4 subscales. The total score is the sum of the mean subscale scores. Higher scores are more symptomatic.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Experimental 1","description":"vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks\n\nvilazodone: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved."},{"id":"OG001","title":"Placebo Capsules (Sugar Pill)","description":"Placebo capsules matched to the drug dose for 8 weeks\n\nplacebo capsules: placebo capsules matched to drug capsules."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","lowerLimit":"1.55","upperLimit":"2.24"},{"groupId":"OG001","value":"2.08","lowerLimit":"1.63","upperLimit":"2.53"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.05","statisticalMethod":"Regression, Linear","paramType":"Mean Difference (Final Values)","paramValue":"-0.19","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.75","ciUpperLimit":"-0.08"}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Adverse Events","description":"A 17 item checklist of general adverse and withdrawal symptoms. It will be used at baseline and Week 12. Adverse events will be obtained by subject report at Week 4 and Week 8.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline and Week 12","groups":[{"id":"OG000","title":"Experimental 1","description":"vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks\n\nvilazodone: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved."},{"id":"OG001","title":"Placebo Capsules (Sugar Pill)","description":"Placebo capsules matched to the drug dose for 8 weeks\n\nplacebo capsules: placebo capsules matched to drug capsules."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants That Were Satisfied or Very Satisfied","description":"Patient global rating of satisfaction with medication reported on a scale of 0 to 5 (very satisfied).","populationDescription":"all participants with at least one treatment response.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Experimental 1","description":"vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks\n\nvilazodone: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved."},{"id":"OG001","title":"Placebo Capsules (Sugar Pill)","description":"Placebo capsules matched to the drug dose for 8 weeks\n\nplacebo capsules: placebo capsules matched to drug capsules."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"75"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sheehan Global Ratings of Symptom (Hot Flash)Interference","description":"Global ratings on a 10-point scale of the degree that symptoms interfere overall, with work, social activities and family life.","reportingStatus":"NOT_POSTED","timeFrame":"Change from Baseline at Week 8"},{"type":"PRIMARY","title":"Daily Diary Ratings of Severity of Hot Flashes","description":"Hot flash severity will be recorded daily in the am and pm on a scale of 0 (none) to 3 (severe). The frequency of hot flashes was the number reported. The severity of hot flashes was rated on a scale of 0 (none) to 3 (severe). 7-day averages were calculated for baseline, week 4 and week 8 and a mean daily score was obtained for analysis. Baseline values were the means of the first 2 screen weeks. Possible range of the severity scale for the daily mean was 0 (none) to 3 (severe).","populationDescription":"all participants randomized to treatment","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"Week 8.","groups":[{"id":"OG000","title":"Experimental 1","description":"vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks\n\nvilazodone: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved."},{"id":"OG001","title":"Placebo Capsules (Sugar Pill)","description":"Placebo capsules matched to the drug dose for 8 weeks\n\nplacebo capsules: placebo capsules matched to drug capsules."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","lowerLimit":"1.05","upperLimit":"1.80"},{"groupId":"OG001","value":"1.39","lowerLimit":"1.02","upperLimit":"1.76"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.05","statisticalMethod":"Regression, Linear","paramType":"Mean Difference (Final Values)","paramValue":"-0.22","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.74","ciUpperLimit":"-0.21"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","eventGroups":[{"id":"EG000","title":"Experimental 1","description":"vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks\n\nvilazodone: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.","seriousNumAffected":0,"seriousNumAtRisk":24,"otherNumAffected":17,"otherNumAtRisk":24},{"id":"EG001","title":"Placebo Capsules (Sugar Pill)","description":"Placebo capsules matched to the drug dose for 8 weeks\n\nplacebo capsules: placebo capsules matched to drug capsules.","seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":6,"otherNumAtRisk":12}],"otherEvents":[{"term":"diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":12}]},{"term":"nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":12}]},{"term":"headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":24},{"groupId":"EG001","numAffected":2,"numAtRisk":12}]},{"term":"dry mouth","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":24},{"groupId":"EG001","numAffected":3,"numAtRisk":12}]},{"term":"dehydration","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":3,"numAtRisk":12}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Ellen Freeman","organization":"University of Pennsylvania","email":"freemane@mail.med.upenn.edu","phone":"215-662-3329"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D019584","term":"Hot Flashes"}],"ancestors":[{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069503","term":"Vilazodone Hydrochloride"}],"ancestors":[{"id":"D010879","term":"Piperazines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D001572","term":"Benzofurans"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D007211","term":"Indoles"}]}},"hasResults":true}